'Embracing gene therapy era', Stifel starts Sensorion at 'buy'

Sensorion SA

21/03/2024 12:11

** Stifel initiates coverage of French biopharma company
Sensorion  ALSEN.PA  with a "buy" rating, saying the share price
does not fully appreciate its drug pipeline which includes
"exciting" gene therapy treatments 
    ** The broker points to the company's SENS-501
hearing-restoration gene therapy, and its legacy SENS-401
treatment
    ** "If investors were disappointed by the mixed results of
SENS-401 in SSNHL, we believe there is value in the pipeline
(...) that is not entirely reflected in the share price" -
Stifel 
    ** The broker expects "an intense newsflow" in 2024 for
Sensorion, with first clinical data for SENS-501 expected this
year, while SENS-401 should be on the market by 2028
    ** "Sensorion is now fully embracing the gene therapy era,"
says Stifel, adding that this field of medicine is "exciting",
also in view of more approvals for such treatments in recent
years
    ** It sets its PT on the stock at 1.50 euros ($1.64), which
is 87.5% higher than the company's Wednesday closing price of
0.80 euros 
    ** All five analysts that cover Sensorion rate the stock
"strong buy" or "buy"


($1 = 0.9167 euros)

 (Reporting by Olivier Sorgho)
 ((Olivier.Sorgho@thomsonreuters.com))